Prescription medication · Muscle Relaxant
methocarbamol
Also sold as Robaxin. This medicine treats the discomfort caused by painful muscle problems.
Data updated 2026-05-15
- 21,191
- FDA reportsModerately reported
- 1
- Recall record
What the data shows
methocarbamol (Robaxin) is a prescription Muscle Relaxant, reported at a middle-of-the-pack volume (21,191 FDA reports).
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
methocarbamol (Robaxin) is a prescription Muscle Relaxant. This medicine treats the discomfort caused by painful muscle problems.
Methocarbamol is a muscle relaxant. It helps to relieve discomfort from painful muscle problems.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$0.03/unit
Generic Available
Yes (16 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
NADAC price trail: METHOCARBAMOL 500 MG TABLET
Same CMS presentation as the headline generic unit price above (3 effective dates). Adjacent % compares consecutive NADAC releases for this description only, not a patient out-of-pocket quote. Latest step: -2.2% vs prior release.
| Effective | NADAC / unit | vs prior | NDCs |
|---|---|---|---|
| February 21, 2024 | $0.0424/EA | - | 1 |
| April 17, 2024 | $0.0327/EA | -22.9% | 1 |
| December 18, 2024 | $0.0320/EA | -2.2% | 23 |
What it does
This medicine treats the discomfort caused by painful muscle problems.
Common side effects
Drowsiness, Dizziness, Lightheadedness
Key warnings
Methocarbamol can interact with alcohol and other drugs that affect your central nervous system.
The sections below are summarized in plain English from methocarbamol's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Methocarbamol is a central nervous system depressant. It likely works by making you feel calm and relaxed. This may help to relieve muscle discomfort.
Side Effects (from patient reports)
Based on 21,191 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for methocarbamol, by number of reports
- Pain
Pain
1,639 reports
- Nausea
Nausea
1,565 reports
- Fatigue
Fatigue
1,531 reports
- Headache
Headache
1,201 reports
- Diarrhoea
Diarrhoea
1,078 reports
- Fall
Fall
1,046 reports
- Dyspnoea
Dyspnoea
995 reports
- Arthralgia
Arthralgia
963 reports
- Dizziness
Dizziness
909 reports
- Anxiety
Anxiety
884 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for methocarbamol each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where methocarbamol sits
methocarbamol has more FDA adverse-event reports than 56% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is methocarbamol; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 21,191 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
21,191
Reports Mentioning Death
1,643
7.8% of reports — not proof of cause
Hospitalization Reports
6,345
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | PAIN | 1,639 |
| 2 | NAUSEA | 1,565 |
| 3 | FATIGUE | 1,531 |
| 5 | HEADACHE | 1,201 |
| 6 | DIARRHOEA | 1,078 |
| 7 | FALL | 1,046 |
| 8 | DYSPNOEA | 995 |
| 9 | ARTHRALGIA | 963 |
| 10 | DIZZINESS | 909 |
| 11 | ANXIETY | 884 |
| 12 | BACK PAIN | 884 |
| 14 | DEPRESSION | 797 |
| 15 | VOMITING | 789 |
| 16 | PAIN IN EXTREMITY | 762 |
| 17 | CHRONIC KIDNEY DISEASE | 761 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Methocarbamol can interact with alcohol and other drugs that affect your central nervous system. Be careful when taking these together.
Common Questions
Can I drink alcohol while taking this medicine?
Will this medicine make me sleepy?
Can I drive while taking this medicine?
What should I do if I have side effects?
Can I take this with other medicines?
How long does it take for this medicine to work?
What if this medicine doesn't relieve my pain?
Can I stop taking this medicine when I feel better?
Is it okay to take this medication if I have kidney problems?
Can children take this medicine?
What are the common side effects of methocarbamol?
What drug class is methocarbamol?
What pregnancy or breastfeeding source fields are listed for methocarbamol?
Has methocarbamol been recalled?
Active Recalls
Lack of Assurance of Sterility: Media fill with bacterial contamination
Somerset Therapeutics Private Limited
Related Medications in Muscle Relaxant
Other drugs grouped near methocarbamol - same-class peers and common alternatives.
baclofen
Lioresal, Gablofen
Baclofen is a muscle relaxant.
Compare with methocarbamol →
botulinum toxin A
Botox
Botox is a drug that blocks nerve signals to muscles.
Compare with methocarbamol →
carisoprodol
Soma
Carisoprodol is a muscle relaxant.
Compare with methocarbamol →
chlorzoxazone
Parafon Forte
Chlorzoxazone is a muscle relaxant.
Compare with methocarbamol →
cyclobenzaprine
Flexeril, Amrix
Cyclobenzaprine is a muscle relaxant.
Compare with methocarbamol →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for methocarbamol: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 21,191.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 7.75%.
- dofetilide Δ 0.00 pts · 10,302 reports · Class III Antiarrhythmic 7.76%death share
- cannabidiol Δ 0.01 pts · 22,227 reports · Cannabinoid (Anticonvulsant) 7.77%death share
- cefdinir Δ 0.02 pts · 7,348 reports · Third-Generation Cephalosporin 7.77%death share
- etodolac Δ 0.05 pts · 5,880 reports · Nonsteroidal Anti-Inflammatory Drug (NSAID) 7.81%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on methocarbamol
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for methocarbamol
The FDA label for methocarbamol (sold under brand names such as Robaxin) classifies it as a prescription-only medication in the Muscle Relaxant class. This medicine treats the discomfort caused by painful muscle problems. Official labeling lists 5 commonly reported side effects, including Drowsiness, Dizziness, Lightheadedness.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 21,191 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS shows a generic unit cost of $0.03.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history (currently 1 recall record on file), and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: August 1, 2020
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages